{
    "organizations": [],
    "uuid": "85c2872c2c3e95d2fc046cc587b19f5d1829e524",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-shenzhen-hepalink-pharmaceutical-a/brief-shenzhen-hepalink-pharmaceutical-amends-fy-2017-net-profit-outlook-idUSL4N1PP2D6",
    "ord_in_thread": 0,
    "title": "BRIEF-Shenzhen Hepalink Pharmaceutical amends FY 2017 net profit outlook",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 30(Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd :\n* Says net profit for FY 2017 to be 150 million yuan to 210 million yuan\n* Says in the previous outlook, the company expected the net profit for FY 2017 to be 70 million yuan to 150 million yuan\n* Says the net profit of FY 2016 was 396.9 million yuan\nSource text in Chinese: goo.gl/EbCCVu\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-30T14:18:00.000+02:00",
    "crawled": "2018-01-31T16:17:38.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "shenzhen",
        "hepalink",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "net",
        "profit",
        "fy",
        "million",
        "yuan",
        "million",
        "yuan",
        "say",
        "previous",
        "outlook",
        "company",
        "expected",
        "net",
        "profit",
        "fy",
        "million",
        "yuan",
        "million",
        "yuan",
        "say",
        "net",
        "profit",
        "fy",
        "million",
        "yuan",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}